ライフサイエンスコーパス: phase 2 clinical trial

1 cohort study within a randomized, controlled phase 2 clinical trial.

2 Cancer Institute open-label, nonrandomized, phase 2 clinical trial.

3 om vemurafenib-treated HCL patients within a phase 2 clinical trial.

4 se-induced hearing loss in young adults in a phase 2 clinical trial.

5 ansferase inhibitor R115777 (Zarnestra) in a phase 2 clinical trial.

6 SWOG S1115 was a randomized phase 2 clinical trial.

7 ow ready for repurposing for tuberculosis in phase 2 clinical trials.

8 ous tumor-infiltrating lymphocytes (TILs) in phase 2 clinical trials.

9 , AZD-6244, which is currently being used in phase 2 clinical trials.

10 Most agents are in phase 2 clinical trials.

11 pheral neuropathy in experimental models and phase 2 clinical trials.

12 In phase 2 clinical trials, A(2A) antagonists (istradefylli

13 CRLX101 is currently in phase 2 clinical trials, and human data from several of

14 Conventional phase 2 clinical trials are typically single-arm experim

15 ditions and is currently being progressed to phase 2 clinical trials as a treatment for Alzheimer's d

16 andomized, placebo-controlled, double-masked phase 2 clinical trial at a research center specializing

17 We did a blinded, phase 2 clinical trial at Stanford University.

18 In this phase 2 clinical trial, basimglurant did not demonstrate

19 In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demo

20 e in this area and is currently undergoing 3 phase 2 clinical trials by Corbus Pharmaceuticals.

21 Randomized, open-label, phase 2 clinical trial comparing selumetinib vs chemothe

22 A phase 2 clinical trial conducted at 2 academic medical c

23 ucing ligand (TRAIL) has shown efficacy in a phase 2 clinical trial, development of resistance to TRA

24 a and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance

25 olates collected as part of an international phase 2 clinical trial (FAST II) evaluating telavancin f

26 day 28, on a multicenter, randomized, 4-arm phase 2 clinical trial for newly diagnosed acute GVHD.

27 a specific inhibitor of Ras-Erk signaling in phase 2 clinical trials for cancer.

28 scovery of miravirsen, which is currently in phase 2 clinical trials for treatment of hepatitis C vir

29 espiratory distress syndrome (ARDS), and two phase 2 clinical trials have shown a trend toward benefi

30 the development of prostate cancer, several phase 2 clinical trials have shown an inhibitory effect

31 n against homologous parasites in one of two phase 2 clinical trials; however, despite its ability to

32 We did a randomised, open-label, phase 2 clinical trial (HPTN 067/ADAPT) of oral PrEP wit

33 nistration of IPI-504 as a single agent in a phase 2 clinical trial in patients with NSCLC, specifica

34 , a BACE1 active site inhibitor that reached phase 2 clinical trials in AD.

35 MLN8237 is currently in phase 1 and phase 2 clinical trials in patients with advanced malign

36 lso known as TP-434, is currently undergoing phase 2 clinical trials in patients with complicated int

37 STA-5326 currently is being evaluated in phase 2 clinical trials in patients with Crohn disease a

38 Phase 2 clinical trials in the United Kingdom and the Ne

39 A confirmatory phase 2 clinical trial is ongoing to assess ceritinib ac

40 t miRNA-based therapy, miravirsen, is now in phase 2 clinical trials, making the reality of these the

41 in development (which are now in phase 1 or phase 2 clinical trials) might be for specific lysosomal

42 A single arm phase 2 clinical trial of 15 patients with breast cancer

43 In a phase 2 clinical trial of annual alemtuzumab for treatme

44 sician-initiated, open-label, single-center, phase 2 clinical trial of brentuximab vedotin for CD30+

45 A phase 2 clinical trial of CT-011 in combination with len

46 Based on these data, a phase 2 clinical trial of forodesine has been initiated

47 -MS) is an ongoing, multicenter, single-arm, phase 2 clinical trial of HDIT/HCT for patients with RRM

48 6 patients with CLL enrolled in a single-arm phase 2 clinical trial of ibrutinib for CLL between Marc

49 themia vera were enrolled into a prospective phase 2 clinical trial of reduced-intensity allogeneic h

50 ng phase 1 results, we report the results of phase 2 clinical trials of dasatinib in patients with im

51 Phase 2 clinical trials of i.v. hu14.18-IL-2 (i.v.-IC) i

52 used as an early microbiological endpoint in phase 2 clinical trials of tuberculosis treatment on the

53 4 by either GKT137831, which is currently in phase 2 clinical trials, or VAS-2870 attenuated NLRP3 in

54 In a follow-up placebo-controlled phase 2 clinical trial, rDEN4 Delta 30 was administered

55 Usher syndrome type 2 who participated in a phase 2 clinical trial received CNTF delivered by an enc

56 n multiple animal models, and in Phase 1 and Phase 2 clinical trials, SAP affects several aspects of

57 phocytic leukemia has been investigated in a phase 2 clinical trial that included an initial treatmen

58 of scientifically sound, biomarker-informed phase 2 clinical trials that can be initiated by academi

59 ogeldanamycin, 17-AAG) is now progressing to Phase 2 clinical trials, there is a pressing need to ide

60 a GE2270 A derivative, LFF571, has completed phase 2 clinical trials, thus demonstrating the potentia

61 ional, unblinded, nonrandomized single group phase 2 clinical trial to assess the need for radiothera

62 nsed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immuno

63 We performed a phase 2 clinical trial to evaluate the efficacy and safe

64 were performed as part of a U.S. phase 1 or phase 2 clinical trial under a Food and Drug Administrat

65 andomized, double-blind, placebo-controlled, phase 2 clinical trial was conducted in US medical cente

66 A phase 2 clinical trial was conducted to evaluate the ant

67 Thus, phase 2 clinical trial was initiated to study the effect

68 peptide), a histone deacetylase inhibitor in phase 2 clinical trials, was studied in K562 cells, gran

69 In this phase 2 clinical trial, we assessed three successive coh

70 double-blind, placebo-controlled, randomised phase 2 clinical trial, we enrolled adults with amyotrop

71 re, randomised, open-label, non-comparative, phase 2 clinical trial, we enrolled eligible adults 18-7

72 lacebo-controlled, double-blind, randomised, phase 2 clinical trial, we enrolled patients (aged 22-89

73 A randomized, placebo-controlled phase 2 clinical trial with a parallel, untreated, nonra

74 Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activ